Quantification and pharmacokinetics of blood-brain barrier disruption in humans

Journal of Neurosurgery

Volumn 85, Issue 6, 1996, Pages 1056-1065

  Zünkeler, Bernhard ^a   Carson, Richard E ^g   Olson, Jeff ^b   Blasberg, Ronald G ^c   DeVroom, Hetty ^g   Lutz, Robert J ^g   Saris, Stephen C ^d   Wright, Donald C ^e   Kammerer, William ^g   Patronas, Nicholas J ^g   Dedrick, Robert L ^g   Herscovitch, Peter ^g   Oldfield, Edward H ^f  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b EMORY CLINIC   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d BROWN UNIVERSITY   (United States)

^e GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^f NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^g NONE

Author keywords

blood brain barrier; blood brain barrier disruption; brain neoplasm; clinical trial; glioma; pharmacokinetics; positron emission tomography

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FOLINIC ACID; MANNITOL; METHOTREXATE; OXYGEN 15; PROCARBAZINE; RUBIDIUM 82; STRONTIUM 82;

ADULT; AGED; ANESTHESIA COMPLICATION; ARTICLE; ASTROCYTOMA; BLOOD BRAIN BARRIER; BONE MARROW TOXICITY; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; FEMALE; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; GLIOMA; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SEIZURE; TREATMENT OUTCOME;

EID: 10544254259     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.1996.85.6.1056     Document Type: Article

References (48)

1. Bergstrom M, Collins P, Ehrin E, et al: Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga]EDTA, [11C]glucose, and [11C]methionine. J Comput Assist Tomogr 7:1062-1066, 1983
2. Blacklock JB, Wright DC, Dedrick RL, et al: Drug streaming during intra-arterial chemotherapy. J Neurosurg 64:284-291, 1986
3. Blasberg RG: Methotrexate, cytosine arabinoside and BCNU concentration in brain afer ventriculocisternal perfusion. Cancer Treat Rep 61:625-631, 1977
4. Blasberg RG, Groothuis DR, Molnar P: A review of hyperosmotic blood-brain barrier disruption in seven experimental brain tumor models, in Johansson BB, Owman V, Widner H (eds): Pathophysiology of the Blood-Brain Barrier. Amsterdam: Elsevier, 1990, pp 193-216
5. Bobo RH, Laske DW, Akbasak A, et al: Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 91:2076-2080, 1994
6. Bode U, Magrath IT, Bleyer WA, et al: Active transport of methotrexate from cerebrospinal fluid in humans. Cancer Res 40:2184-2187, 1980
7. Breithaupt H. Küenzlen E: Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following injections of high-dose methotrexate. Cancer Treat Rep 66:1733-1741, 1982
8. Brem H, Piantadosi S, Burger PC, et al: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345:1008-1012, 1995
9. Brooks DJ, Beaney RP, Lammertsma AA, et al: Quantitative measurement of blood-brain barrier permeability using rubidium-82 and positron emission tomography. J Cereb Blood Flow Metab 4:535-545, 1984
10. 15O: comparison of methods. J Cereb Blood Flow Metab (Suppl) 7:S578, 1987 (Abstract)
11. Dedrick RL: Arterial drug infusion: pharmacokinetic problems and pitfalls. J Natl Cancer Inst 80:84-89, 1988
12. 82Rb. II: Clinical data and validation of technique. Phys Med Biol 34:1785-1794, 1989
13. 82Rb/PET studies of blood-brain barrier permeability. Phys Med Biol 33:61-74, 1988
14. 82Rb. I: Error analysis and computer simulations. Phys Med Biol 34:1773-1784, 1989
15. 82Rb positron emission tomography. J Comput Assist Tomogr 11:563-570, 1987
16. Earnest F IV, Kelly PJ, Scheithauer BW, et al: Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 166: 823-827, 1988
17. Fenstermacher JD: Drug transfer across the blood-brain barrier, in Breimer DD, Speiser P (eds): Topics in Pharmaceutical Sciences. Amsterdam: Elsevier, 1983, pp 143-154
18. Fenstermacher JD, Gazendam J: Intra-arterial infusions of drugs and hyperosmotic solutions as ways of enhancing CNS chemotherapy. Cancer Treat Rep 65 (Suppl 2):27-37, 1981
19. Fishman RA: Is there a therapeutic role for osmotic breaching of the blood-brain barrier? Ann Neurol 22:298-299, 1987 (Editorial)
20. Fishman RA: Osmotic opening of the blood-brain barrier. Ann Neurol 24:680, 1988 (Letter)
21. Fishman RA, Chan PH: Liposome entrapment of drugs and enzymes to enable passage across the blood-brain barrier, in Johansson BB, Owman C, Widner H (eds): Pathophysiology of the Blood-Brain Barrier. Amsterdam: Elsevier, 1990, pp 131-139
22. Goldstein GW: Endothelial cell-astrocyte interactions. A cellular model of the blood-brain barrier. Ann NY Acad Sci 529: 31-39, 1988
23. Groothuis DR, Blasberg RG: Osmotic opening of the blood-brain barrier. Ann Neurol 24:682-684, 1988 (Letter)
24. 82Rb: the effect of dexamethasone and whole brain radiation therapy. Ann Neurol 18:636-646, 1985
25. Junck L, Koeppe RA, Greenberg HS: Mixing in the human carotid artery during carotid drug infusion studies with PET, J Cereb Blood Flow Metab 9:681-689, 1989
26. Lammertsma AA, Brooks DJ, Frackowiak RSJ, et al: A method to quantitate the fractional extraction of rubidium-82 across the blood-brain barrier using positron emission tomography. J Cereb Blood Flow Metab 4:523-543, 1984
27. Long DM: Capillary ultrastructure and the blood-brain barrier in human malignant brain tumors. J Neurosurg 32:127-144, 1970
28. Lutz RJ, Dedrick RL, Boretos JW, et al: Mixing studies during intracarotid artery infusions in an in vitro model. J Neurosurg 64:277-283, 1986
29. Morrison PF, Laske DW, Bobo H, et al: High-flow microinfusion: tissue penetration and pharmakodynamics. Am J Physiol 266:R292-R305, 1994
30. Neuwelt EA, Balaban E, Diehl J. et al: Successful treatment of primary central nervous system lymphomas with chemotherapy after osmotic blood-brain barrier opening. Neurosurgery 12: 662-671, 1983
31. Neuwelt EA, Barnett PA, Bigner DD, et al: Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. Proc Natl Acad Sci USA 79:4420-4423, 1982
32. Neuwelt EA, Dahlborg SA: Chemotherapy administered in conjunction with osmotic blood-brain barrier modification in patients with brain metastases. J Neurooncol 4:195-207, 1986
33. Neuwelt EA, Diehl JT, Vu LH, et al: Monitoring of methotrexate delivery in patients with malignant brain tumors after osmotic blood-brain barrier disruption. Ann Intern Med 94: 449-454, 1981
34. Neuwelt EA, Frenkel EP: Is there a therapeutic role for blood-brain barrier disruption? Ann Intern Med 93:137-139, 1980 (Editorial)
35. Neuwelt EA, Hill SA, Frenkel EP: Osmotic blood-brain barrier modification and combination chemotherapy: Concurrent tumor regression in areas of barrier opening and progression in areas distant to barrier opening. Neurosurg 15:362-366, 1984
36. Neuwelt EA, Howieson J, Frenkel EP, et al: Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgery 19:573-582, 1986
37. Pardridge WM: Chimeric peptides as a vehicle for neuropharmaceutical delivery through the blood-brain barrier, in Johansson BB, Owman C, Wiedner H (eds): Pathophysiology of the Blood-Brain Barrier. Amsterdam: Elsevier, 1990, pp 221-229
38. Rall DP, Zubrod CG: Mechanisms of drug absorption and excretion. Passage of drugs in and out of the central nervous system. Annu Rev Pharmacol 2:109-128, 1962
39. Rapoport SI: Osmotic opening of the blood-brain barrier. Ann Neurol 24:677-679, 1988
40. Rapoport SI, Fredericks WR, Ohno K, et al: Quantitative aspects of reversible osmotic opening of the blood-brain barrier. Am J Physiol 238:R421-R431, 1980
41. Rapoport SI, Hori M, Klatzo I: Testing of a hypothesis for osmotic opening of the blood-brain barrier. Am J Physiol 223: 323-331, 1972
42. Rapoport SI, Ohno K, Fredericks WR, et al: Regional cerebrovascular permeability to (14C)-sucrose after osmotic opening of the blood-brain barrier. Brain Res 150:653-657, 1978
43. Robinson PJ, Rapoport SI: Size selectivity of blood-brain barrier permeability at various times after osmotic opening. Am J Physiol 253:R459-R466, 1987
44. Saris SC, Blasberg RG, Carson RE, et al: Intravascular streaming during carotid artery infusions. Demonstration in humans and reduction using diastole-phased pulsatile administration. J Neurosurg 74:763-772, 1991
45. Shapiro WR: Osmotic opening of the blood-brain barrier. Ann Neurol 24:680-682, 1988
46. Stewart DJ, Grahovac Z, Hugenholtz H, et al: Combined intraarterial and systemic chemotherapy for intracerebral tumors. Neurosurgery 21:207-214, 1987
47. Vance RB, Kapp JP: Supraophthalmic carotid infusion with low dose cisplatin and BCNU for malignant glioma. J Neurooncol 2:287-290, 1986
48. Zünkeler B, Carson RE, Olson J, et al: Hyperosmolar blood-brain barrier disruption in baboons: an in vivo study using positron emission tomography and rubidium-82. J Neurosurg 84:494-502, 1996